Disease · MONDO_0010837

primary hyperparathyroidism

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. primary hyperparathyroidism. Diseases, record MONDO_0010837. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0010837

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: primary hyperparathyroidism; Open Targets
Open Targets ID: MONDO_0010837; Open Targets
Other names: familial benign hypercalcemia (disorder), familial primary hyperparathyroidism, primary hyperparathyroidism (disease), primary hyperparathyroidism (disorder); Open Targets
Disease Ontology: DOID:11202; Disease Ontology
MeSH: D049950; MeSH
NCI Thesaurus: C48280; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 9 drugs, from ClinicalTrials.gov; Open Targets

Drugs9

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CINACALCET	CHEMBL1201284	Small molecule	Phase 3	ClinicalTrials.gov	10	10	10	Drugs and targets
DENOSUMAB	CHEMBL1237023	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
EVOCALCET	CHEMBL4297621	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
CHOLECALCIFEROL	CHEMBL1042	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
AMILORIDE	CHEMBL945	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
EPLERENONE	CHEMBL1095097	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
ALENDRONIC ACID	CHEMBL870	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
CALCIUM CARBONATE	CHEMBL1200539	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
LISINOPRIL	CHEMBL419213	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets9

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CASR	Extracellular calcium-sensing receptor	2	Calcium sensing receptor positive allosteric modulator	Phase 3	https://conductscience.org/library/genes/846	Drugs and targets
ACE	Angiotensin-converting enzyme	1	Angiotensin-converting enzyme inhibitor	Unknown	https://conductscience.org/library/genes/1636	Drugs and targets
FDPS	Farnesyl pyrophosphate synthase	1	Farnesyl diphosphate synthase inhibitor	Unknown	https://conductscience.org/library/genes/2224	Drugs and targets
NR3C2	Mineralocorticoid receptor	1	Mineralocorticoid receptor antagonist	Phase 2/3	https://conductscience.org/library/genes/4306	Drugs and targets
SCNN1A	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2/3	https://conductscience.org/library/genes/6337	Drugs and targets
SCNN1B	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2/3	https://conductscience.org/library/genes/6338	Drugs and targets
SCNN1G	Amiloride-sensitive sodium channel, ENaC	1	Amiloride-sensitive sodium channel, ENaC blocker	Phase 2/3	https://conductscience.org/library/genes/6340	Drugs and targets
TNFSF11	Tumor necrosis factor ligand superfamily member 11	1	Tumor necrosis factor ligand superfamily member 11 inhibitor	Phase 3	https://conductscience.org/library/genes/8600	Drugs and targets
VDR	Vitamin D3 receptor	1	Vitamin D receptor agonist	Phase 2/3	https://conductscience.org/library/genes/7421	Drugs and targets

Trials15

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00928408	PRIMARA: A Prospective Descriptive Observational Study to Review Mimpara (Cinacalcet) Use in Patients With Primary Hyperparathyroidism in Clinical Practice		305	2013-11-14	Hyperparathyroidism, Primary	CINACALCET	Its record names the disease	ClinicalTrials.gov
NCT02525796	Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism	Phase 2/3	69	2023-05-03	Primary Hyperparathyroidism	AMILORIDE, CINACALCET, EPLERENONE	Its record names the disease	ClinicalTrials.gov
NCT00975221	Efficacy and Safety Study of Cinacalcet for the Treatment of Hypercalcemia in Patients With Primary Hyperparathyroidism Unable to Undergo Parathyroidectomy	Phase 3	67	2016-01-25	Hyperparathyroidism, Primary, Hypercalcemia	CINACALCET	Its record names the disease	ClinicalTrials.gov
NCT00674154	Effect of Vitamin D Treatment in Primary Hyperparathyroidism	Phase 2/3	46	2013-10-16	Vitamin D Deficiency, Primary Hyperparathyroidism, Hypercalcemia	CHOLECALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT03027557	Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.	Phase 3	46	2021-05-25	Primary Hyperparathyroidism, Parathyroid Adenoma, Parathyroid Hyperplasia	CINACALCET, DENOSUMAB	Its record names the disease	ClinicalTrials.gov
NCT01691781	The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study	Not applicable	41	2017-08-10	Hyperparathyroidism	LISINOPRIL	Its record names the disease	ClinicalTrials.gov
NCT03280264	Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism	Phase 3	18	2021-05-27	Parathyroid Carcinoma, Primary Hyperparathyroidism	EVOCALCET	Its record names the disease	ClinicalTrials.gov
NCT00982722	Vitamin D Supplementation After Parathyroid Surgery	Not applicable	150		Primary Hyperparathyroidism	CALCIUM CARBONATE, CHOLECALCIFEROL	Its record names the disease	ClinicalTrials.gov
NCT01889134	OPG/Soluble RANKL (sRANKL) and Bone Mineral Density in Primary Hyperparathyroidism	Not applicable	112		Primary Hyperparathyroidism	ALENDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02227264	Primary Hyperparathyroidism: Short-term Calcimimetics Treatment - Relevance for Parathyroid Surgery Decisions?	Not applicable	110		Primary Hyperparathyroidism	CINACALCET	Its record names the disease	ClinicalTrials.gov

1 to 10 of 15

See all 15 trials

Comparisons in its trials3

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Vitamin D vs Placebo: serious adverse events	1 of 20	1 of 22	42	NCT00674154	Trial comparisons
Primary Hyperparathyroidism vs Normal: deaths from any cause	0 of 12	0 of 15	27	NCT01691781	Trial comparisons
Primary Hyperparathyroidism vs Normal: serious adverse events	0 of 12	0 of 15	27	NCT01691781	Trial comparisons

Papers from its trials12

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
28522130	RESULT	1	PubMed
26435425	RESULT	1	PubMed
25414430	RESULT	1	PubMed
24115138	RESULT	1	PubMed
24026893	RESULT	1	PubMed
19837909	RESULT	1	PubMed
15522938	RESULT	1	PubMed
35018442	DERIVED	1	PubMed
32333877	DERIVED	1	PubMed
31595982	DERIVED	1	PubMed

1 to 10 of 12

See all 12 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0010837

GET https://conductscience.org/api/diseases/v1/MONDO_0010837/drugs

API reference For AI assistants